Innovative Mechanochemical Processes to synthesize green ACTIVE pharmaceutical ingredients.

HealthHORIZON-RIAID: 101057286
EC Contribution
โ‚ฌ74,387
Consortium Size
20 orgs
Start Year
2022
โ–ถSummary

The environmental impact of the pharmaceutical industry is a huge problem. The production and use of pharmaceuticals cause high CO2 emissions, contamination of soils, biota, and water, and even dangers to human health through carcinogenic impurities. Especially the use of solvents is a major problem. The European Green Deal has led to strict regulations on environmental pollution by the pharma industry, causing manufacturers to move outside of the EU due to the high costs associated with green pharma. This results in supply chain fragility and low crisis preparedness in Europe. New methods to produce pharmaceuticals in a green, efficient, and economically friendly way are required.The IMPACTIVE project brings together the expertise and knowledge from two COST Actions and will develop novel green methods to produce active pharmaceutical ingredients (APIs) using mechanochemistry as a disruptive technology (as acknowledged by IUPAC). Mechanochemistry uses mechanical processes, such as ball milling, twin-screw extrusion, resonant acoustic mixing, and spray drying, to induce chemical reactions. The advantages of mechanochemistry include: no solvent use, high efficiency, low costs, and reduced energy use and CO2 emission. Upon completion of the project, we will provide proof-of-concept at a small pilot scale of the use of mechanochemistry to produce 6 APIs from 3 different families of compounds. Based on a recent study, switching to mechanochemistry can reduce terrestrial ecotoxicity and CO2 emissions by more than 85%, while production costs were reduced with 12%. The results of the IMPACTIVE project will thus enable pharmaceutical manufacturers to move back to Europe while minimizing environmental pollution.Through our strong dissemination and communication strategy we will ensure that the project?s results are shared with scientists, the pharmaceutical industry, and stakeholders from regulatory and public authorities to achieve maximum impact.

Consortium (20)

๐Ÿ‡ซ๐Ÿ‡ท UNIVERSITE DE MONTPELLIERFR
coordinator
๐Ÿ‡ช๐Ÿ‡ธ AGATA COMUNICACION CIENTIFICA SLES
partner
๐Ÿ‡ซ๐Ÿ‡ท AXLR SATT OCCITANIE MEDITERRANEEFR
partner
๐Ÿ‡ฉ๐Ÿ‡ช BUNDESANSTALT FUER MATERIALFORSCHUNG UND -PRUEFUNGDE
partner
๐Ÿ‡ฎ๐Ÿ‡น CONSORZIO INTERUNIVERSITARIO PERLO SVILUPPO DEI SISTEMI A GRANDE INTERFASEIT
partner
๐Ÿ‡ต๐Ÿ‡น DES SOLUTIO - SOLUCOES E CONSULTORIA CIENTIFICA LDAPT
partner
๐Ÿ‡ซ๐Ÿ‡ท ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIERFR
partner
๐Ÿ‡จ๐Ÿ‡ญ HAUTE ECOLE SPECIALISEE DE SUISSE OCCIDENTALECH
partner
๐Ÿ‡ต๐Ÿ‡น IST-ID ASSOCIACAO DO INSTITUTO SUPERIOR TECNICO PARA A INVESTIGACAO E O DESENVOLVIMENTOPT
partner
๐Ÿ‡ฌ๐Ÿ‡ง JOHNSON MATTHEY PLCGB
partner
๐Ÿ‡ฉ๐Ÿ‡ช MAX PLANCK INSTITUT FUER KOHLENFORSCHUNGDE
partner
๐Ÿ‡จ๐Ÿ‡ญ NOVARTIS PHARMA AGCH
partner
๐Ÿ‡ฉ๐Ÿ‡ช RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHENDE
partner
๐Ÿ‡จ๐Ÿ‡ญ SIGMA-ALDRICH PRODUCTION GMBHCH
partner
๐Ÿ‡ณ๐Ÿ‡ฑ STICHTING RADBOUD UNIVERSITEITNL
partner
๐Ÿ‡ช๐Ÿ‡ช TALLINNA TEHNIKAรœLIKOOLEE
partner
๐Ÿ‡ฎ๐Ÿ‡ฑ TECHNION - ISRAEL INSTITUTE OF TECHNOLOGYIL
partner
๐Ÿ‡ฎ๐Ÿ‡ช THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLINIE
partner
๐Ÿ‡ฎ๐Ÿ‡น UNIVERSITA DEGLI STUDI DI CAGLIARIIT
partner
๐Ÿ‡ง๐Ÿ‡ช UNIVERSITE CATHOLIQUE DE LOUVAINBE
partner